--- title: "CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial" type: "News" locale: "en" url: "https://longbridge.com/en/news/288238438.md" description: "CStone Pharmaceuticals reported strong ASCO data for its trispecific antibody CS2009, showing efficacy in lung and colorectal cancers with a favorable safety profile. Following U.S. regulatory clearance and global enrollment of nearly 300 patients, the company plans to launch a Phase III global trial by late 2026." datetime: "2026-06-01T00:37:43.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/288238438.md) - [en](https://longbridge.com/en/news/288238438.md) - [zh-HK](https://longbridge.com/zh-HK/news/288238438.md) generator: "portal-rs" --- # CStone’s CS2009 Posts Strong ASCO Data as Company Prepares Global Phase III Trial ### Claim 55% Off TipRanks - Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. - Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter CStone Pharmaceuticals ( (HK:2616) ) has issued an update. CStone Pharmaceuticals reported new clinical data for its core asset CS2009, a trispecific antibody targeting PD-1, VEGF and CTLA-4, presented at the ASCO Annual Meeting. The drug showed strong efficacy signals in first-line non-small cell lung cancer across PD-L1 expression levels, including high response and disease control rates in both monotherapy and chemo-combination settings. In later-line lung cancer, CS2009 demonstrated sustained tumor shrinkage and meaningful responses in patients previously treated with immunotherapy and chemotherapy, suggesting potential to overcome resistance. The candidate also generated encouraging activity in traditionally immunotherapy-refractory colorectal cancer and other solid tumors, while maintaining a favorable safety profile with manageable high-grade adverse events and no excess toxicity typical of CTLA-4 combinations. With nearly 300 patients enrolled globally and recent U.S. regulatory clearance, CStone plans to launch a Phase III global multi-regional registrational trial for CS2009 by the end of 2026. The company positions CS2009 as a potential next-generation immunotherapy backbone, which, if successful, could strengthen its competitive standing in oncology and expand treatment options for patients with lung, colorectal and other solid tumors. **More about CStone Pharmaceuticals** CStone Pharmaceuticals is a biopharmaceutical company focused on developing innovative oncology therapies. Its pipeline includes immuno-oncology drugs and targeted therapies, with a particular emphasis on multispecific antibodies aimed at treating lung cancer, colorectal cancer and other solid tumors in global markets including China, Australia and the U.S. **Average Trading Volume:** 13,617,117 **Technical Sentiment Signal:** Strong Buy **Current Market Cap:** HK$12.7B For a thorough assessment of 2616 stock, go to TipRanks’ Stock Analysis page. ### Related Stocks - [02616.HK](https://longbridge.com/en/quote/02616.HK.md) - [159615.CN](https://longbridge.com/en/quote/159615.CN.md) - [512290.CN](https://longbridge.com/en/quote/512290.CN.md) - [159849.CN](https://longbridge.com/en/quote/159849.CN.md) - [520690.CN](https://longbridge.com/en/quote/520690.CN.md) - [159837.CN](https://longbridge.com/en/quote/159837.CN.md) - [159992.CN](https://longbridge.com/en/quote/159992.CN.md) - [159316.CN](https://longbridge.com/en/quote/159316.CN.md) - [516930.CN](https://longbridge.com/en/quote/516930.CN.md) - [513700.CN](https://longbridge.com/en/quote/513700.CN.md) - [513120.CN](https://longbridge.com/en/quote/513120.CN.md) - [159859.CN](https://longbridge.com/en/quote/159859.CN.md) - [520880.CN](https://longbridge.com/en/quote/520880.CN.md) - [513060.CN](https://longbridge.com/en/quote/513060.CN.md) - [159506.CN](https://longbridge.com/en/quote/159506.CN.md) - [588130.CN](https://longbridge.com/en/quote/588130.CN.md) - [159892.CN](https://longbridge.com/en/quote/159892.CN.md) - [159102.CN](https://longbridge.com/en/quote/159102.CN.md) - [516500.CN](https://longbridge.com/en/quote/516500.CN.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [588250.CN](https://longbridge.com/en/quote/588250.CN.md) ## Related News & Research - [CStone says China NMPA clears IND for CS5007 EGFR/HER3 bispecific ADC](https://longbridge.com/en/news/296540686.md) - [CStone’s Trispecific Cancer Antibody CS2009 Secures Dual Rapid Oral Slots at ESMO 2026](https://longbridge.com/en/news/293139912.md) - [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md) - [CStone Pharmaceuticals shareholders pass AGM resolutions](https://longbridge.com/en/news/290616544.md) - [CStone Shareholders Approve All AGM Resolutions, Renew Capital Mandates and CEO Equity Awards](https://longbridge.com/en/news/290618548.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**